Skip to main content
OpenTrials
Completed

NCT Number: NCT02000479

Influence of Exercise Therapy on Insulin Resistance in Patients With Heart Failure

The purpose of this study is to investigate the effects of a combined training programme on insulin resistance, exercise tolerance, muscle strength, body composition and cardiac function in chronic heart failure patients.

It is assumed that the above mentioned clinical parameters will improve due to physical exercise.

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

About this study

  • Background and study aims During the last decades, the prevalence of (pre)diabetes but also of chronic heart failure (CHF) has increased dramatically. Somehow, both conditions are linked, but the mechanisms involved have not been completely clarified yet. It is clear that the presence of (pre)diabetes in CHF patients affects morbidity and mortality. Although feasibility, safety and beneficial effects of exercise training in CHF are generally acknowledged, its effects on insulin resistance are not well understood. Therefore, the presented study aims to investigate the effect of ET on insulin resistance and the possible link with cardiac function, exercise tolerance, muscle strength and body composition in CHF patients.
  • What does the study involve?

A randomized controlled study (n=30) will be performed over a period of 12 weeks. Following study inclusion, baseline measurements will be performed in 1 week. They include:

  • a maximal exercise test on a bicycle ergometer to assess exercise tolerance,
  • two oral glucose tolerance tests to assess fasting and post-exercise insulin resistance,
  • a venous blood sample to determine HbA1c, blood lipids, BNP,
  • a muscle strength measurement on a isokinetic dynamometer,
  • assessment of body composition via dual energy x-ray absorptiometry,
  • cardiac echography,
  • questionnaires to assess health-related quality of life,
  • a questionnaire (IPAQ) and a pedometer (3 days) to assess physical activity. Following baseline measurements, subjects will be randomized to a control group (CON, n=10) and an exercise intervention group (EX, n=20), matching for gender and reduced/preserved ejection fraction and glucose tolerance. Hereafter, CON will receive usual care and will be advised to maintain their normal lifestyle, EX subjects will be enrolled in a 12-week training program. Following 6 (MID) and 12 (POST) weeks of exercise training including progressive training load adaptations, baseline measurements will be repeated in all patients.
  • What are the possible benefits and risks of participating?
  • Benefits: patients receive a free training program with personal and professional supervision. After completing the study, they receive a report with personal results and evaluation of training effects.
  • Risks: the usual risks of exercise tolerance testing and exercise training in a CHF population are limited because training sessions are held in the supervised conditions of the Jessa hospital and because training characteristics are according to guidelines of the European Society of Cardiology. Exposure to x-rays during body composition assessment is very low, almost negligible.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • diagnosis of chronic heart failure for at least 6 months
  • clinically stable (not hospitalized) for more than 3 months prior to the onset of the study
  • optimal medical therapy.

Exclusion criteria

  • any contra-indication for exercise therapy,
  • glucose lowering medical therapy,
  • active lifestyle with regular physical activity.

Treatment and study plan

Training

Other

Other names: 12 weeks of combined exercise training

Primary outcomes

  1. insulin sensitivity (insulin profile)

    Time frame: change from baseline to 12 weeks

    glucose and insulin concentration measurements in blood during oral glucose tolerance test

Secondary outcomes

  1. Exercise tolerance

    Time frame: change from baseline to 12 weeks

    maximal cardiopulmonary exercise test on a bicycle ergometer

  2. HbA1c, blood lipids, BNP

    Time frame: change from baseline to 12 weeks

  3. Muscle strength

    Time frame: change from baseline to 12 weeks

    maximal strength and strength endurance tested on a isokinetic dynamometer

  4. Body composition

    Time frame: change from baseline to 12 weeks

    dual energy x-ray absorptiometry

  5. cardiac function

    Time frame: change from baseline to 12 weeks

    echocardiography

  6. Health-related quality of life

    Time frame: change from baseline to 12 weeks

    MLHFQ and Eq5d

Sponsors and collaborators

Lead sponsor

Hasselt University

Other

Collaborators

  • Jessa Hospital

Registry information

Important dates

Study start
2011
Primary completion
2011
Study completion
2011
First posted
Dec 4, 2013
Registry last updated
Dec 10, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.